


# CETP

## Cholesteryl ester transfer protein

HDAC Inhibitor:  
Vorinostat (SAHA)



HDAC (Histone deacetylase)

as LDL and VLDL.

CETP catalyses the exchange of cholesteryl ester and triglyceride between HDL and apoB containing lipoprotein particles. The role of CETP in modulating plasma HDL cholesterol levels in humans is well established and there have been significant efforts to develop CETP inhibitors to increase HDL cholesterol for the treatment of coronary artery disease.

Cholesteryl ester transfer protein (CETP) is a plasma glycoprotein that promotes reverse cholesterol transport via the exchange of cholesteryl ester (CE) and triglyceride (TG) among lipoproteins. Cholesteryl ester transfer protein (CETP) promotes reverse cholesterol transport via exchange of cholesteryl ester and triglyceride among lipoproteins. CETP has a central role in lipoprotein metabolism.

CETP, a hydrophobic plasma glycoprotein, is a promising target for raising circulating HDL cholesterol (HDL-C) concentrations in humans. CETP is secreted primarily from the liver and plays a critical role in HDL metabolism by facilitating the exchange of cholesteryl esters (CE) from HDL for triglycerides (TG) in apoB-containing lipoproteins, such

## CETP Inhibitors & Modulators

### Anacetrapib

(MK-0859)


Cat. No.: HY-12090

**Bioactivity:** Anacetrapib is a potent **CETP** inhibitor, with **IC<sub>50</sub>**s of 7.9±2.5 nM and 11.8±1.9 nM for rhCETP and C13S CETP mutant, respectively.

**Purity:** 98.39%

**Clinical Data:** Phase 3

**Size:** 10mM x 1mL in DMSO,  
5 mg, 10 mg, 50 mg, 100 mg



### CKD-519


Cat. No.: HY-116078

**Bioactivity:** CKD-519 is a selective and potent **cholesteryl ester transfer protein (CETP)** inhibitor, which inhibits CETP-mediated transfer of cholesteryl ester in human serum with an **IC<sub>50</sub>** of 2.3 nM <sup>[1]</sup>.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 250 mg, 100 mg, 500 mg



### Dalcetrapib

(JTT-705; RO4607381)


Cat. No.: HY-14950

**Bioactivity:** Dalcetrapib (JTT-705; RO-4607381) is a rhCETP inhibitor with IC<sub>50</sub> of 0.2 μM that increases the plasma HDL cholesterol.

**Purity:** 99.46%

**Clinical Data:** Phase 3

**Size:** 10mM x 1mL in DMSO,  
5 mg, 10 mg, 50 mg, 100 mg



### Evacetrapib

(LY2484595)


Cat. No.: HY-13327

**Bioactivity:** Evacetrapib is a potent and selective of **CETP** inhibitor, which inhibits human recombinant CETP protein ( **IC<sub>50</sub>** 5.5 nM) and CETP activity in human plasma ( **IC<sub>50</sub>** 36 nM) in vitro.

**Purity:** 99.33%

**Clinical Data:** Phase 3

**Size:** 10mM x 1mL in DMSO,  
5 mg, 10 mg, 50 mg, 100 mg



### Torcetrapib

(CP-529414)

Cat. No.: HY-12089

**Bioactivity:** Torcetrapib(CP-529414) is a CETP inhibitor with IC<sub>50</sub> of 37 nM, elevates HDL-C and reduces nonHDL-C in plasma.

**Purity:** 99.35%

**Clinical Data:** Phase 3

**Size:** 10mM x 1mL in DMSO,  
5 mg, 10 mg, 50 mg

